SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-24-084844
Filing Date
2024-10-03
Accepted
2024-10-03 07:01:12
Documents
15
Period of Report
2024-10-03
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea021662501-8k_aldeyra.htm   iXBRL 8-K 25287
2 ALDEYRA THERAPEUTICS, INC. PRESS RELEASE DATED OCTOBER 3, 2024 ea021662501ex99-1_aldeyra.htm EX-99.1 14151
3 GRAPHIC image_001.jpg GRAPHIC 3807
  Complete submission text file 0001213900-24-084844.txt   228401

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE aldx-20241003.xsd EX-101.SCH 3057
5 XBRL LABEL FILE aldx-20241003_lab.xml EX-101.LAB 34916
6 XBRL PRESENTATION FILE aldx-20241003_pre.xml EX-101.PRE 22817
17 EXTRACTED XBRL INSTANCE DOCUMENT ea021662501-8k_aldeyra_htm.xml XML 3854
Mailing Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421
Business Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421 781-761-4904
Aldeyra Therapeutics, Inc. (Filer) CIK: 0001341235 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36332 | Film No.: 241349884
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)